News and insights

Search all news & insights

    Latest news

    Show
    news from

    Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress

    Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

    Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call

    Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO

    Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

    Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA)

    View all news

    Latest insights & articles

    Show
    insights & articles from

    Sorry, we can't find any insights or articles

    View all insights & articles

    Latest publications & presentations

    Show presentations from

    Autolus Corporate Presentation - June 2024

    Download PDF (1.64Mb)

    Autolus Corporate Presentation - November 2023

    Download PDF (2.23Mb)

    Autolus Corporate Presentation - July 2023

    Download PDF (1.82Mb)

    Autolus Corporate Presentation - March 2023

    Download PDF (1.58Mb)

    Autolus Corporate Presentation - January 2023

    Download PDF (1.57Mb)

    Autolus Corporate Presentation - August 2022

    Download PDF (1.79Mb)
    View all publications & presentations

    Search